(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DBT: Vol 31 No 1

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Long-acting injectable antipsychotics in schizophrenia

Bol Inf Farmacoter Navar. 2023;31 (1):1-19
https://doi.org/10.54095/BITN20233101EN


Antipsychotics serve as the cornerstone of pharmacological treatment for schizophrenic disorders, including both the management of acute episodes and the prevention of relapse. Longacting injectable antipsychotics (LAIAs) are intended to improve treatment compliance, thereby reducing the risk of relapse and hospitalization. The marketing of LAIAs has increased over the past few years, consequently expanding the range of active substances and extending dosing intervals (bi-weekly, monthly, quarterly and semi-annually). This new situation represents a qualitative change in the available therapeutic approaches for schizophrenia, although a risk/benefit assessment is required, and the prescribing efficiency from an overall patient health perspective needs to be studied.
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

 

 

 

 

Suggestions/Comments  

Authors:

JUAN JOSÉ BELOQUI LIZASO
MARÍA SÁNCHEZ RUIZ DE GORDOA
VIRGINIA BASTERRA GORTARI
Navarre Health Service. Mental Health Management

Government of Navarre

Contact us | Accessibility | Legal notice | Site map